menu

Medical Education: Insights on an IBS-D Therapy that Can Help Relieve Symptoms

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
x
Hello, there.

INDICATION

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION
  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
  • There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.
Read Additional Important Safety Information >>
CONTINUE TO PROGRAM
Salix Xifaxan

Insights on an IBS-D Therapy that Can Help Relieve Symptoms

Insights on an IBS-D Therapy that Can Help Relieve Symptoms
RestartResume

Please see below for Important Safety Information and full Prescribing Information.

  • Overview

    Please click here for full Prescribing Information.

    Irritable bowel syndrome with diarrhea can have a significant impact on patients’ daily activities due to debilitating symptoms like abdominal pain and diarrhea, both of which could be a result of alterations in the gut microbiota. Joining us to discuss XIFAXAN (rifaximin), the only FDA-approved treatment that alters the gut microbiota in IBS-D, is Dr. Gregory Sayuk.

  • Indication and Important Safety Information

    INDICATION

    XIFAXAN® (rifaximin) 550 mg tablets are indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

    IMPORTANT SAFETY INFORMATION

    • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
    • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
    • There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.
    • Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.
    • In clinical studies, the most common adverse reactions for XIFAXAN in IBS-D (≥2%) were nausea (3%) and ALT increased (2%).
    • INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.
    • XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.

    To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    Please click here for full Prescribing Information.

    ©2020 Salix Pharmaceuticals or its affiliates. XIFI.0349.USA.19

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 5/31/20